Successful outcomes using combination therapy of interleukin-2 and interferon-α for renal cell carcinoma patients with lung metastasis

Japanese Journal of Clinical Oncology

Volumn 40, Issue 7, 2010, Pages 684-689

  Akaza, Hideyuki ^a   Kawai, Koji ^a   Tsukamoto, Taiji ^b   Fujioka, Tomoaki ^c   Tomita, Yoshihiko ^d   Kitamura, Tadaichi ^e   Ozono, Seiichiro ^f   Miki, Tsuneharu ^g   Naito, Seiji ^h   Zembutsu, Hitoshi ⁱ   Nakamura, Yusuke ⁱ  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c IWATE MEDICAL UNIVERSITY   (Japan)

^d YAMAGATA UNIVERSITY   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^h KYUSHU UNIVERSITY   (Japan)

ⁱ UNIVERSITY OF TOKYO   (Japan)

Author keywords

Combination therapy; Cytokine; Interferon ; Interleukin 2; Lung metastasis; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; IMUNACE; INTERLEUKIN 2; UNCLASSIFIED DRUG;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; AGED; ANOREXIA; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; EOSINOPHILIA; ERYTHROPENIA; FATIGUE; FEMALE; FEVER; HEMATOCRIT; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; LEUKOPENIA; LUNG METASTASIS; LYMPHOCYTOPENIA; MALE; NAUSEA; NEUTROPENIA; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77954451346     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq027     Document Type: Article

References (25)

1. Vogelzang NJ, Priest ER, Borden L. Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup. J Urol 1992;148:1247-8.
2. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000;163:408-17.
3. Klapper JA, Downey SG, Smith FO, Yang JC, Hughes MS, Kammula US, et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the Surgery Branch at the National Cancer Institute between 1986 and 2006. Cancer 2008;113:293-301.
4. Belldegrun AS, Klatte T, Shuch B, LaRochelle JC, Miller DC, Said JW, et al. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies. Cancer 2008;113:2457-63.
5. Aso Y, Tazaki H, Umeda T, Marumo K. A phase II study of S-6820 (recombinant interleukin-2) on renal cell carcinoma. Biotherapy 1989;3:999-1007 (in Japanese).
6. Aso Y, Homma Y, Tazaki H, Marumo K, Satomi Y, Tsukamoto T, et al. A phase II trial of S-6820 (recombinant interleukin-2) on renal cell carcinoma refractory to interferon. Hinyokigeka 1995;8:75-86 (in Japanese).
7. Hayashi T, Miyagawa Y, Tsujimura A, Nonomura N, Minami M, Okuyama A. A case of renal cell carcinoma with multiple lung metastases refractory to interferon-α showing complete remission by interleukin-2 monotherapy. Int J Urol 2006;13:805-8.
8. Kobayashi M, Ikeda H, Nukui A, Suzuki K, Sugaya Y, Yuzawa M, et al. Clinical outcome and prognostic survival factors in patients with advanced renal cell carcinoma treated with very low-dose interleukin-2, interferon-α, and tegafur-uracil: a single-institution experience. Int J Clin Oncol 2008;13:257-62.
9. Biswas S, Eisen T. Immunotherapeutic strategies in kidney cancer-when TKIs are not enough. Nature Rev Clin Oncol 2009;6:478-87.
10. Akaza H, Tsukamoto T, Onishi T, Miki T, Kinouchi T, Naito S. A low-dose combination therapy of interleukin-2 and interferon-α is effective for lung metastasis of renal cell carcinoma: a multicenter open study. Int J Clin Oncol 2006;11:434-40.
11. Japanese Urological Association and Japanese Society of Pathology. Response criteria for urological cancer treatment. Jpn J Urol 1992;83:447-72.
12. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-96.
13. Naito S, Yamamoto N, Takayama T, Muramoto M, Shinohara N, Nishiyama K, et al. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol 2010;57:317-26.
14. Negrier S, Escudier B, Lasset C, Douillard J-Y, Savary J, Chevreau C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 1998;338:1272-8.
15. McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23:133-41.
16. Vaglio A, Alberici F, Maggiore U, Buti S, Potenzoni D, Passalacqua R, et al. Chronically administered immunotherapy with low-dose IL-2 and IFN-alpha in metastatic renal cell carcinoma: a feasible option for patients with a good prognostic profile. Oncology 2009;76:69-76.
17. Buzio C, Andrulli S, Santi R, Pavone L, Passalacqua R, Potenzoni D, et al. Long-term immunotherapy with low-dose interleukin-2 and interferon-α in the treatment of patients with advanced renal cell carcinoma. Cancer 2001;92:2286-96.
18. Pavone L, Andrulli S, Santi R, Majori M, Buzio C. Long-term treatment with low doses of interleukin-2 and interferon-alpha: immunological effects in advanced renal cell cancer. Cancer Immunol Immunother 2001;50:82-6.
19. Stafford HS, Saltzstein SL, Shimasaki S, Sanders C, Downs TM, Robins Sadler G. Racial/ethnic and gender disparities in renal cell carcinoma incidence and survival. J Urol 2008; 179:1704-8.
20. Miyake H, Kurahashi T, Takenaka T, Inoue T, Fujisawa F. Clinical outcome of combined immunotherapy with interferon-α and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma. Urol Oncol 2009;27:598-603.
21. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34.
22. Escudier B, Szczylik C, Hutson TE, Demkow T, Staehler M, Rolland F, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:1280-9.
23. Akaza H, Tsukamoto T, Murai M, Nakajima K, Naito S. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 2008;37:755-62.
24. Motzer RJ, Hutson TE, Tomczak P, Michaelson D, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
25. Motzer RJ, Michaelson MD, Rosenberg J, Bukowski RM, Curti BD, George DJ, et al. Sunitinib efficacy against advanced renal cell carcinoma. J Urol 2007;178:1883-7.